Purchase Order SPE2DP25P0663
- Not listed
- The U.S. Department of Defense, through its Medical Supply Chain division, awarded a firm fixed price purchase order valued at $10,585.32 to Eagle Pharmaceuticals, Inc. for Dantrolene Sodium F, with performance expected to conclude by September 19, 2025. This contract is designated as a Total Small Business set-aside and was awarded on September 4, 2025, with work to be performed in Westwood, New Jersey. Eagle Pharmaceuticals, a specialized pharmaceutical manufacturer headquartered in...
- The U.S. Department of Defense, through its Medical Supply Chain division, awarded a $10,585.32 firm fixed-price purchase order to Eagle Pharmaceuticals, Inc. for Dantrolene Sodium F on September 4, 2025. The contract, designated as a Total Small Business set-aside, has an ultimate completion date of September 19, 2025 and will be performed in Westwood, New Jersey. Eagle Pharmaceuticals, a specialized pharmaceutical manufacturer headquartered in Woodcliff Lake, New Jersey, has established itself...
- This federal contract award, valued at $58,219.26, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Eagle Pharmaceuticals, Inc., a for-profit pharmaceutical manufacturer, for the supply of Dantrolene Sodium F medication. The contract has a total small business set-aside designation. The original solicitation, which was posted on March 27, 2025 and had a due date of April 2, 2025, requested the procurement of 33 units of Dantrolene Sodium F medication across 11 line...
- The U.S. Department of Defense, through its Medical Supply Chain division, awarded a delivery order contract valued at $10,585.32 to Eagle Pharmaceuticals, Inc. for the supply of Ryanodex 250 mg vials. The contract, awarded on August 18, 2025, with an ultimate completion date of August 21, 2025, was issued without set-aside designation under firm fixed-price terms. Performance will take place in Westwood, New Jersey. This delivery order is issued under Eagle Pharmaceuticals' existing Federal...
- Eagle Pharmaceuticals, Inc. has been awarded a $4,874.13 firm fixed price delivery order by the Defense Logistics Agency Troop Support Medical (DLA Troop Support Medical) to supply 250mg vials of the drug Ryanodex. As the prime contractor, Eagle Pharmaceuticals will deliver the specified pharmaceutical products to DLA Troop Support Medical's place of performance in Westwood, New Jersey by November 15, 2023. No major subcontractors or joint venture partners are involved. The delivery order was...
- This federal contract award, with a total ceiling value of $5,292.66, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Eagle Pharmaceuticals, Inc., a for-profit pharmaceutical manufacturer. The contract is a delivery order (SPE2D325F5036) for the supply of Ryanodex, a 250mg injectable medication used for treating and preventing malignant hyperthermia in high-risk patients. The contract is a firm fixed-price arrangement with a period of performance ending on January 31,...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Eagle Pharmaceuticals, Inc., a for-profit pharmaceutical manufacturer. The contract, valued at $5,080.62, is for the supply of 250mg vials of the drug Ryanodex, which is used to treat and prevent malignant hyperthermia in high-risk patients. This delivery order contract is not set aside and is part of a larger Federal Supply Schedule (FSS) contract between Eagle...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,292.66 firm fixed-price delivery order is for the supply of dantrolene sodium powder, a medication used to treat malignant hyperthermia. The contract has an ultimate completion date of April 18, 2025 and does not have a set-aside designation, indicating open competition. Amerisourcebergen...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on September 9, 2025, by the Defense Medical Supply Chain for the supply of Fosphenytoin 500 mg PE/10 mL (10 mL vials) with a ceiling value of $1,189.39. This firm fixed-price delivery order is not set-aside and is scheduled for ultimate completion by September 10, 2025. The award represents a routine pharmaceutical procurement fulfilling federal medical...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Epinephrine 0.3mg auto-injectors (2-count packages). Valued at $89,797.16 with a firm fixed price structure, this non-set-aside competitive award is scheduled for completion by September 10, 2025, with performance at the contractor's Conshohocken, Pennsylvania facility. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery...
The U.S. Department of Defense Medical Supply Chain has awarded a $10,585.32 firm fixed-price purchase order to Eagle Pharmaceuticals, Inc. for Dantrolene Sodium F, a critical injectable medication. The contract, designated as a Total Small Business set-aside, was awarded on September 3, 2025, with an ultimate completion date of September 18, 2025. Performance will take place in Westwood, New Jersey. Eagle Pharmaceuticals, a specialized pharmaceutical manufacturer headquartered in Woodcliff Lake, New Jersey, has established itself as a key supplier of critical injectable medications to federal agencies, particularly the Department of Defense and Department of Veterans Affairs. This award represents part of Eagle Pharmaceuticals' broader role within the federal medical supply chain, where the company provides specialized pharmaceutical products to support military medical readiness and healthcare operations. As a registered small business contractor, Eagle Pharmaceuticals leverages its existing Federal Supply Schedule contract with the VA Veterans Health Administration—valued at $30.9 million and effective through January 2029—to efficiently deliver essential medications across multiple federal entities. The company's consistent track record of supplying high-demand pharmaceutical products through the Defense Logistics Agency positions it as a reliable partner for the government's ongoing healthcare and medical logistics requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.6k | 9/3/25 |